Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roger Williams

Interventional Cardiology Tupelo, MS Medical Doctor

NPI 1568572709 CMS profile 162122

499 Gloster Creek Vlg Ste A2, Cardiology Associates Of North Ms, Tupelo, MS 38801

Open in the dashboard

General payments

$7,120

231 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,897 paid to institutions, not to them · program year 2025

Through program year 2025, Roger Williams of Tupelo, MS is reported in the CMS Open Payments database as having received $7,120 across 231 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,897 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 48th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,450 39
2024 General $993 33
2023 General $1,036 35
2022 General $977 38
2021 General $876 32
2020 General $531 15
2019 General $1,257 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roger Williams
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Roger Williams were reported at $1,450. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Roger Williams Interventional Cardiology median Middle half National median
2019 $1,257 $1,097 $329–$3,048 $163
2020 $531 $473 $161–$1,480 $114
2021 $876 $677 $233–$1,827 $132
2022 $977 $978 $333–$2,724 $149
2023 $1,036 $1,136 $382–$2,986 $160
2024 $993 $1,181 $395–$3,326 $164
2025 $1,450 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $671 13 payments
  2. Medtronic, Inc. $569 21 payments
  3. Boston Scientific Corporation $560 10 payments
  4. Penumbra, Inc. $494 6 payments
  5. Thrombolex, Inc. $402 4 payments
  6. Abiomed $309 3 payments
  7. Novartis Pharmaceuticals Corporation $299 21 payments
  8. Philips Electronics North America Corporation $275 14 payments
  9. Biotronik Inc. $241 4 payments
  10. Janssen Pharmaceuticals, Inc $234 19 payments
  11. Other $3,067 116 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,064 229 payments
  2. Travel and Lodging $54 1 payment
  3. Education $2 1 payment
Products named General payments · program years 2019–2025
  1. Indigo System $494 6 payments
  2. Bashir Endovascular Catheter $402 4 payments
  3. SYMPLICITY G3 $331 15 payments
  4. XARELTO $314 20 payments
  5. Impella $241 2 payments
  6. General - Vascular Intervention $227 2 payments
  7. Xience Sierra Coronary Stent $227 2 payments
  8. ALPHAVAC $224 2 payments
  9. VERQUVO $212 11 payments
  10. (5044) MCOT $205 13 payments
  11. Other $4,480 175 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

4,422

Median for Interventional Cardiology: 2,236

Drug cost

$347,974

Median for Interventional Cardiology: $380,412

Branded share of claims

25.2%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 127 $97,045
Eliquis Apixaban Brand 100 $84,663
Repatha Sureclick Evolocumab Brand 75 $66,368
Entresto Sacubitril/Valsartan Brand 21 $20,650
Brilinta Ticagrelor Brand 25 $14,454
Praluent Pen Alirocumab Brand 21 $12,176
Ranolazine Er Ranolazine Brand 96 $9,158
Metoprolol Succinate Generic 389 $4,550
Clonidine Generic 42 $3,209
Ezetimibe Generic 165 $2,842

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$339,170

Of which drugs: $55,536

Medicare patients

1,877

Average age 75

Services billed

11,033

937 women, 940 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Arthritis 53%
Diabetes 42%
Atrial fibrillation 37%
Heart failure 33%
Chronic kidney disease 33%
COPD 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, inclisiran, 1 mg J1306 Office 19 5,680 $53,694
Injection, regadenoson, 0.1 mg J2785 Office 85 340 $1,817

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $57
$57 — —
VYNDAQEL
  • PFIZER INC. $34
$34 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $29
$29 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $18
$18 — —
Repatha
  • Amgen Inc. $17
$17 75 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record